F10 and interstitial lung disease: Subgroup analysis showed that a higher risk of incident ILD for the FXa inhibitor group vs the warfarin group was consistent regardless of age; sex; CHA2DS2-VASc score; HAS-BLED score; use of angiotensin system inhibitor, amiodarone, statin, or β-blocker; or risk of stroke or major bleeding (for example, age <75 years: 0.24 vs 0.12 per 100 patient-years [HR, 1.72; 95% CI, 1.24-2.41]; age ≥75 years: 0.37 vs 0.22 per 100 patient-years [HR, 1.58; 95% CI, 1.12-2.23]; P = .73) (eFigure 2 in the Supplement).